← FDA DRUG APPROVALS

FDA ANDA · ANDA209105

ATOVAQUONE

Sponsor: LUPIN

APPLICATION
ANDA209105
TYPE
ANDA
ORIGINAL APPROVAL
2018-09-11
LATEST ACTION
2019-09-19
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Discontinued

Products

ATOVAQUONEDiscontinued
ATOVAQUONE 750MG/5ML · SUSPENSION · ORAL

Approval history

2019-09-19Labeling · Supplement 5 · standardAP
2019-09-19Labeling · Supplement 3 · standardAP
2018-09-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →